---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-330537"
form_type: "8-K"
ticker: "STOK"
cik: "0001623526"
company_name: "Stoke Therapeutics, Inc."
filed_at: "2026-08-03T20:05:17+00:00"
generated_at: "2026-08-03T20:07:18.196665+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Stoke Therapeutics Q2 net loss $61.6M; Phase 3 EMPEROR enrollment complete at 162 patients

## Summary
- Net loss of $61.6M ($0.93 per share) vs $23.5M loss in Q2 2025; revenue fell to $9.3M from $13.8M.
- Cash, equivalents and marketable securities $420M (incl. $65.7M post-quarter ATM sale); funds operations to potential 2028 launch.
- Phase 3 EMPEROR study of zorevunersen enrolled 162 patients; data readout expected Q3 2027.
- Pre-NDA meeting with FDA scheduled H2 2026; rolling NDA submission to begin Q1 2027.
- Phase 1 OSPREY study of STK-002 for ADOA: sentinel cohort dosed, initial data anticipated H1 2027.

## SEC filing metadata
- accession: 0001193125-26-330537
- form_type: 8-K
- ticker: STOK
- cik: 0001623526
- company_name: Stoke Therapeutics, Inc.
- filed_at: 2026-08-03T20:05:17+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1623526/000119312526330537/0001193125-26-330537-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1623526/000119312526330537/stok-20260803.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-330537
- JSON: https://secwatch.observer/filing/0001193125-26-330537.json
- Plain text: https://secwatch.observer/filing/0001193125-26-330537.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.